Hiring has cooled across the US, yet health care just added fresh jobs while salaries on new postings ticked higher. That mix of slower overall growth, firmer labor demand and rising pay can reshape cost pressures and revenue potential for large healthcare stocks. This article walks through three US healthcare companies from our screener that look closely tied to these job market shifts, and explains how each might be helped or hurt by them.

The stocks highlighted below are just a starting sample, and the full screen surfaced 33 more U.S. healthcare companies with equally compelling stories around quality scores and exposure to key parts of the sector that are not covered here. To go deeper, head straight into the Healthcare Sector Stocks screener to identify, filter and analyze the healthcare stocks that best fit your own conviction.

Privia Health Group (PRVA)

Privia Health Group is a US based physician enablement company that helps doctors deliver value based care through shared technology, data and practice management support. It generates about US$2.25b of revenue from healthcare facilities and services, and its business is fully focused on the US market. The company currently has a market value of roughly US$3.0b.

Some investors interested in healthcare job trends may want to keep Privia Health on their radar. The company sits at the heart of physician practices at a time when the sector is adding more jobs, and management reports very low provider attrition and rising numbers of at risk contracts, which can deepen its role in value based care. At the same time, thin net margins, modest ROE and recent insider selling raise questions about how much of that growth narrative may already be reflected in the current share price. The contrast between recent earnings momentum and these pressure points is what makes Privia Health a stock that may warrant closer inspection.

Privia Health appears to be caught between increasing at-risk contracts and tight net margins, which may be obscuring where the real upside and pressure points lie. Get the full picture in the 4 key rewards and 1 important warning sign

Build your own value based care shortlist

Privia Health Group and the two other stocks in this article all surfaced from a single Simply Wall St screen, but the real edge comes when you shape the filters yourself. Use our flexible Screener to mix metrics like valuation, future growth, balance sheet strength and risks, or jump straight into our curated Investing Ideas.

agilon health (AGL)

agilon health runs a subscription style model that pays primary care doctors a per member per month fee to manage the full healthcare needs of senior patients across US communities. While detailed segment revenue data is not disclosed here, the company is firmly positioned in value based care for Medicare age populations. agilon health currently has a market value of about US$1.8b.

The latest US jobs report points to rising health care hiring and firmer wage growth, which plays directly into agilon health’s push to partner more closely with primary care groups on long term, value based contracts. Recent earnings have highlighted progress on medical cost trends, better payer data and efforts to improve operating efficiency. The business still carries a history of losses, choppy membership trends and higher financial risk from its funding mix. For investors who think subscription care models for seniors can scale in a slower, low hire, low fire labor market, agilon health is a story where both the potential upside and the execution risk are central and may warrant a deeper look.

agilon health’s push to tighten medical costs and deepen long term senior care contracts can look like growth waiting for a clearer story. The full analysis report for agilon health could reveal what the current funding mix is really signaling

Centene (CNC)

Centene is a managed care company that provides health coverage and related services to under insured and commercial members across the US through Medicaid, Medicare, Commercial and other health solutions. It generates most of its roughly US$180.3b of revenue from Medicaid at about US$92.6b, with Medicare at US$40.4b, Commercial plans at US$40.7b and Other services such as pharmacy, vision, dental and behavioral health at about US$5.0b. Centene currently carries a market value of roughly US$33.1b.

Centene sits at the center of US public health coverage at a time when health care hiring is still growing even as overall job growth cools. A steadier jobs backdrop with modestly higher wages can support Medicaid and Marketplace enrollment, which is where Centene is pushing for margin recovery, tighter cost control and better use of AI in provider contracting. Earnings are still volatile and the company has a record of losses and high medical costs, so the risk around policy changes, funding and specialty drugs is real. For investors interested in a large, lower P/S healthcare stock tied closely to employment and public coverage trends, the open question is how far this margin recovery story can run before the market fully prices it in.

Centene’s margin recovery story may be stronger than the current P/S ratio suggests, especially with Medicaid and Marketplace exposure tied to a firmer jobs backdrop. The full 3 key rewards and 1 important warning sign could surface the one risk investors are still underestimating

Seeking Alternatives Before The Crowd

Fresh ideas move first. By the time momentum is obvious, early entries are gone and spreads are flying. Spot under the radar stocks while it matters, and aim to get in early.

• Track cash rich companies before they appear on mainstream screens by scanning our hand picked 50 high quality undervalued stocks curated for balance sheet strength and earnings quality.
• Look for potential opportunities in automation by scanning the curated 36 robotics and automation stocks with companies building the hardware and software that could be part of the next wave of productivity momentum.
• Monitor structural power shifts by checking the under the radar 37 power grid technology and infrastructure stocks packed with businesses tied to grid upgrades, reliability and long term infrastructure demand.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.